Rua Câmara Pestana, Nº 6 | Edifício CEDOC II | Gabinete 2.27 1150-082 Lisboa – Portugal
Telefone: 218803127

Hugo Vicente Miranda

Investigador  Investigador Doutorado
Principal Investigator
My research relies in the hypothesis that brain dysmetabolism significantly contributes for the neurodegenerative process underlying Parkinson’s or Alzheimer’s diseases. In agreement, epidemiological findings suggest that dysmetabolism (such as in Diabetes) is an important risk factor for neurodegenerative diseases. Importantly, we identified that protein glycation, a major consequence of hyperglycemia, is a molecular link between these disorders. Therefore, I am focused in understanding how sugar stress and dysmetabolism potentiates neurodegeneration. This will ultimately allow to identify novel therapeutic targets for brain diseases. Besides heading the DysBrainD: Dysmetabolism in Brain Diseases laboratory, I am also affiliate Assistant Professor, involved in the teaching to MSc and PhD programmes at NOVA Medical School. I am also member of the Council of NOVA Medical School.
Insulin-degrading enzyme: an ally against metabolic and neurodegenerative diseases. Sousa L, Guarda M, Meneses MJ, Macedo MP, Vicente Miranda H. J Pathol. 2021 Aug 16. doi: 10.1002/path.5777. Online ahead of print. Hsp27 reduces glycation-induced toxicity and aggregation of alpha-synuclein. Vicente Miranda H*, Chegão A, Oliveira MS, Fernandes Gomes B, Enguita FJ, Outeiro TF*. FASEB J. 2020 May;34(5):6718-6728. doi: 10.1096/fj.201902936R. Epub 2020 Apr 7. Extracellular aggregated alpha synuclein primarily triggers lysosomal dysfunction in neural cells prevented by trehalose. Hoffmann AC, Minakaki G, Menges S, Salvi R, Savitskiy S, Kazman A, Vicente Miranda H, Mielenz D, Klucken J, Winkler J, Xiang W. Sci Rep. 2019 Jan 24;9(1):544. doi: 10.1038/s41598-018-35811-8. Alpha-Synuclein Glycation and the Action of Anti-Diabetic Agents in Parkinson's Disease. König A, Vicente Miranda H, Outeiro TF. J Parkinsons Dis. 2018;8(1):33-43. doi: 10.3233/JPD-171285. Posttranslational modifications of blood-derived alpha-synuclein as biochemical markers for Parkinson's disease. Vicente Miranda H*, Cássio R, Correia-Guedes L, Gomes MA, Chegão A, Miranda E, Soares T, Coelho M, Rosa MM, Ferreira JJ, Outeiro TF*. Sci Rep. 2017 Oct 20;7(1):13713. doi: 10.1038/s41598-017-14175-5. α-synuclein interacts with PrPC to induce cognitive impairment through mGluR5 and NMDAR2B. Ferreira DG, Temido-Ferreira M, Vicente Miranda H, Batalha VL, Coelho JE, Szegö ÉM, Marques-Morgado I, Vaz SH, Rhee JS, Schmitz M, Zerr I, Lopes LV, Outeiro TF. Nat Neurosci. 2017 Nov;20(11):1569-1579. doi: 10.1038/nn.4648. Epub 2017 Sep 25. Glycation potentiates α-synuclein-associated neurodegeneration in synucleinopathies. Vicente Miranda H, Szego ÉM, Oliveira LMA, Breda C, Darendelioglu E, de Oliveira RM, Ferreira DG, Gomes MA, Rott R, Oliveira M, Munari F, Enguita FJ, Simões T, Rodrigues EF, Heinrich M, Martins IC, Zamolo I, Riess O, Cordeiro C, Ponces-Freire A, Lashuel HA, Santos NC, Lopes LV, Xiang W, Jovin TM, Penque D, Engelender S, Zweckstetter M, Klucken J, Giorgini F, Quintas A, Outeiro TF. Brain. 2017 May 1;140(5):1399-1419. doi: 10.1093/brain/awx056. The mechanism of sirtuin 2-mediated exacerbation of alpha-synuclein toxicity in models of Parkinson disease. de Oliveira RM*, Vicente Miranda H*, Francelle L, Pinho R, Szegö ÉM, Martinho R, Munari F, Lázaro DF, Moniot S, Guerreiro P, Fonseca-Ornelas L, Marijanovic Z, Antas P, Gerhardt E, Enguita FJ, Fauvet B, Penque D, Pais TF, Tong Q, Becker S, Kügler S, Lashuel HA, Steegborn C, Zweckstetter M, Outeiro TF. PLoS Biol. 2017 Mar 3;15(3):e2000374. doi: 10.1371/journal.pbio.2000374. eCollection 2017 Mar. Glycation potentiates neurodegeneration in models of Huntington's disease. Vicente Miranda H, Gomes MA, Branco-Santos J, Breda C, Lázaro DF, Lopes LV, Herrera F, Giorgini F, Outeiro TF. Sci Rep. 2016 Nov 18;6:36798. doi: 10.1038/srep36798. Glycation in Parkinson's disease and Alzheimer's disease. Vicente Miranda H, El-Agnaf OM, Outeiro TF. Mov Disord. 2016 Jun;31(6):782-90. doi: 10.1002/mds.26566. Epub 2016 Mar 4. Adenosine A2A Receptors Modulate α-Synuclein Aggregation and Toxicity. Ferreira DG, Batalha VL, Vicente Miranda H, Coelho JE, Gomes R, Gonçalves FQ, Real JI, Rino J, Albino-Teixeira A, Cunha RA, Outeiro TF, Lopes LV. Cereb Cortex. 2017 Jan 1;27(1):718-730. doi: 10.1093/cercor/bhv268. Heat-mediated enrichment of α-synuclein from cells and tissue for assessing post-translational modifications. Vicente Miranda H, Xiang W, de Oliveira RM, Simões T, Pimentel J, Klucken J, Penque D, Outeiro TF. J Neurochem. 2013 Sep;126(5):673-84. doi: 10.1111/jnc.12251. Epub 2013 Apr 25. The sour side of neurodegenerative disorders: the effects of protein glycation. Vicente Miranda H, Outeiro TF. J Pathol. 2010 May;221(1):13-25. doi: 10.1002/path.2682.
2021 iNOVA4Health Grant - Crosstalk between metabolic and neurodegenerative diseases (PI) 2021 Best Poster award at European Physiology Day virtual Meeting 2021 Best Poster award at ENCODS 2021 Award from Sociedade Portuguesa de Diabetologia: IDE as a biomarker (PI) 2018 Award from Sociedade Portuguesa de Diabetologia: Sugar stress in the brain (PI) 2016 FCT Grant - Targeting the glycation defences as a protective strategy for Parkinson's disease (PI) 2014 Poster Award at 8th EHDN Plenary Meeting, Barcelona, Spain 2012 FCT Grant - Alpha-synuclein as a blood biomarker for Parkinson's disease (PI) 2009 Award for best oral presentation at III IMM PhD Student Meeting, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa
http://cedoc.unl.pt/hugo_vicente_miranda/ https://orcid.org/0000-0001-8065-9259 https://www.cienciavitae.pt/portal/2719-3B78-B060 https://novaresearch.unl.pt/en/persons/hugo-vicente-miranda